Nephrology
Membranoproliferative Glomerulonephritis
4
Pipeline Programs↗
1
Active Trials↗
4
Companies Involved↗
Membranoproliferative Glomerulonephritis is an early-stage landscape with 4 programs across 4 companies. The most active players are Apellis Pharmaceuticals, Roche, AstraZeneca. 1 therapy is approved with 3 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Approved1
Analysis
Modality Breakdown
4programs
Small molecule250%
Monoclonal antibody125%
Peptide125%
Modality classified for 100% of 4 pipeline programs.
Analysis
Trial Status
4
clinical trials
Completed2 · 50%
Active, not recruiting1 · 25%
Unknown status1 · 25%
Clinical Trials
Trial Activity
Effect of Rituximab in Treatment of Membranoproliferative Glomerulonephritis
Unknown status·—·Phase 3·NCT03180723·30 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)